Intrexon | XON - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agenus USD 18.74M 16.26M 2026-06
Alaunos Therapeutics USD 354K 1.03M 2026-03
Amgen USD 13.99B 1.95B 2026-06
Anika Therapeutics USD 38.41M 2.61M 2026-06
Arrowhead Research USD 19.68M 127.85M 2026-06
AstraZeneca USD 4.89B 2.67B 2026-06
Bristol-Myers Squibb USD 8.72B 852M 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Heron Therapeutics USD 20.72M 5.4M 2026-06
Incyte USD 3.98B 33.45M 2026-06
Intrexon USD 9.34M 1.77M 2024-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
Ligand Pharmaceuticals USD 1.01B 891.62M 2026-06
MacroGenics USD 113.91M 47.39M 2026-06
MannKind USD 52.93M 95K 2026-06
Merck USD 6.85B 1.52B 2026-06
Novartis USD 7.62B 739M 2026-06
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Thermo Fisher Scientific USD 3.25B 6.6B 2026-03
Veracyte USD 299.52M 36.38M 2026-06
Xencor USD 44.66M 30.49M 2026-06